MARKER THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
MARKER THERAPEUTICS, INC. (MRKR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.04 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-18
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $2.14.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $1.03.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.04.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.68, a 83.85% decline from fiscal 2021.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $28.97.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2016 was $5.84, a 12.18% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $1.04 10-K · filed 2026-03-18 | |||||
| 2022-12-31 | $4.68 10-K · filed 2023-03-22 | |||||
| 2021-12-31 | $28.97 10-K · filed 2023-03-22 | $2.90 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $2.13 10-Q · filed 2020-11-09 | |||||
| 2020-06-30 | $2.13 10-Q · filed 2020-08-10 | |||||
| 2020-03-31 | $2.14 10-Q · filed 2020-05-11 | |||||
| 2016-12-31 | $5.84 10-K · filed 2017-03-14 | |||||
| 2016-09-30 | $6.00 10-Q · filed 2016-11-04 | |||||
| 2015-12-31 | $6.65 10-K · filed 2017-03-14 | |||||
| 2015-09-30 | $0.54 10-Q/A · filed 2016-04-14 | |||||
| 2015-06-30 | $0.54 10-Q/A · filed 2016-04-14 | |||||
| 2015-03-31 | $1.03 10-Q/A · filed 2016-04-14 | |||||
| 2014-09-30 | $1.31 10-Q · filed 2014-11-19 | |||||
| 2012-06-30 | $0.18 10-Q/A · filed 2012-09-12 | |||||
| 2011-02-28 | $0.19 10-Q/A · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |